Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Clin Exp Nephrol ; 24(Suppl 1): 8-16, 2020 Mar.
Article in English | MEDLINE | ID: mdl-31889230

ABSTRACT

BACKGROUND: Dotinurad is a novel selective urate reabsorption inhibitor (SURI) that selectively inhibits the reabsorption of uric acid in renal tubules and promotes the excretion of uric acid into urine. In this study, the effects of age and gender on the pharmacokinetics (PK), pharmacodynamics (PD), and safety of dotinurad were evaluated in healthy subjects. METHODS: An open-label study of a single oral administration of dotinurad 1 mg was conducted in elderly (≥ 65 years) Japanese males and females, and young (20-35 years) males and females (six patients each). RESULTS: Following a single-dose administration of dotinurad, the change in dotinurad plasma concentration showed a similar profile across groups. Regarding the PK parameters, there was no significant difference between elderly and young subjects. On comparing males and females, significant differences were observed in some parameters in elderly subjects. However, these differences in some parameters could not be detected by adjust for body weight. When PD parameters in elderly and young subjects were compared, significant differences were observed in some parameters in male subjects. On comparing males and females, significant differences were observed in some parameters in young subjects; however, the percent change in serum uric acid concentration decreased over time was relatively close for both groups. There were no clinically relevant safety problems. CONCLUSION: Age and gender had no clinically meaningful effect on the PK, PD, and safety of dotinurad. CLINICAL TRIALS: ClinicalTrials.gov identifier: NCT02344875.


Subject(s)
Benzothiazoles/administration & dosage , Uricosuric Agents/administration & dosage , Adult , Age Factors , Aged , Benzothiazoles/adverse effects , Female , Glucuronides/blood , Glucuronides/urine , Healthy Volunteers , Humans , Japan , Male , Metabolic Clearance Rate , Sex Factors , Sulfates/blood , Sulfates/urine , Uric Acid/blood , Uric Acid/urine , Young Adult
2.
Mod Rheumatol ; 30(6): 959-966, 2020 Nov.
Article in English | MEDLINE | ID: mdl-31615315

ABSTRACT

Background: Pentraxin 3 (PTX3) has an important role in inflammation, immunity, and atherosclerosis. Rheumatoid arthritis (RA) is a chronic inflammatory disease featuring both joint damage and atherosclerosis. We investigated whether the plasma PTX3 level was associated with progression of joint destruction and subclinical atherosclerosis in RA patients.Methods: Plasma PTX3 levels were measured in 72 women with RA and 80 female control subjects. In RA patients, we also evaluated clinical characteristics, medications, and at one and three years, joint damage and atherosclerosis. Then we investigated whether PTX3 was associated with progression of joint destruction or an increase of carotid intima-media thickness (IMT).Results: Plasma PTX3 levels were significantly higher in the RA patients than in healthy controls (4.05 ± 2.91 ng/mL vs. 1.61 ± 1.05 ng/mL, p < .001). By multivariate linear regression analysis, the plasma pentraxin 3 level was independently associated with radiographic progression of joint damage for 3 years in the RA patients after adjustment for age, disease duration, body mass index, rheumatoid factor, MMP-3, Disease Activity Score 28-ESR, postmenopausal status, current use of corticosteroids and biologic use. On the other hands, pentraxin 3 was not associated with an increase of carotid intima-media thickness in RA patients.Conclusion: Female RA patients had elevated plasma PTX3 levels compared with control female subjects. PTX3 was independently associated with radiographic progression of joint damage in the RA patients, but not with carotid atherosclerosis.


Subject(s)
Arthritis, Rheumatoid/blood , C-Reactive Protein/analysis , Carotid Artery Diseases/blood , Joints/diagnostic imaging , Serum Amyloid P-Component/analysis , Adult , Arthritis, Rheumatoid/complications , Arthritis, Rheumatoid/pathology , Biomarkers/blood , Body Mass Index , Carotid Artery Diseases/complications , Carotid Artery Diseases/pathology , Carotid Intima-Media Thickness , Disease Progression , Female , Humans , Joints/pathology , Male , Middle Aged
3.
Pharmacol Res Perspect ; 7(6): e00533, 2019 12.
Article in English | MEDLINE | ID: mdl-31788318

ABSTRACT

This study aimed to investigate the pharmacokinetic and pharmacodynamic (PK/PD) profiles of dotinurad, a novel uricosuric agent, and to construct a PK/PD model to predict serum urate (SUA) levels after dotinurad administration in healthy men. PK/PD model was constructed using single-dose study data considering the physiological features of urate handling. Model validation was performed by comparing the predicted SUA levels with the SUA levels in a multiple-dose study. Dotinurad was absorbed rapidly, and its exposure increased proportionally in the tested dose ranges (0.5-20 mg) after a single-dose administration. The PK model after oral administration was described using a one-compartment model with first-order absorption. Effects on SUA and renal urate excretion of dotinurad increased with dose escalation but were apparently saturable at a dose >5 mg. The simple maximal effect (Emax) model was selected as the PD model of dotinurad on renal urate reabsorption, resulting in an estimated Emax of 0.51. The plasma concentration at the half-maximal effect of dotinurad was 196 ng/mL. Other PD parameters were calculated from the change in SUA level or urinary excretion of urate before and after dotinurad administration. The predicted SUA levels, using the PK/PD model, were well-fitted with the observed values. The constructed PK/PD model of dotinurad appropriately described the profiles of dotinurad plasma concentrations and SUA level in multiple administration study.


Subject(s)
Benzothiazoles/pharmacology , Models, Biological , Renal Elimination/drug effects , Uricosuric Agents/pharmacology , Administration, Oral , Adult , Dose-Response Relationship, Drug , Drug Administration Schedule , Half-Life , Healthy Volunteers , Humans , Male , Uric Acid/blood , Uric Acid/metabolism , Young Adult
4.
Ocul Immunol Inflamm ; 27(4): 622-631, 2019.
Article in English | MEDLINE | ID: mdl-29543548

ABSTRACT

Purpose: To compare alcaftadine and olopatadine ophthalmic solutions, and vehicle for preventing allergen-mediated conjunctivitis in Japanese subjects. Methods: Japanese cedar pollen-sensitive subjects were randomized to alcaftadine 0.25%, olopatadine 0.1%, or vehicle. Ocular itching was assessed at 3, 5 (primary outcome), 7, and 15 min post-conjunctival allergen challenge (CAC) and conjunctival hyperemia assessed at 7, 15 (secondary outcome), and 20 min post-CAC. Adverse events were monitored. Results: Overall, 240 subjects were randomized. Alcaftadine 0.25% (challenged 8 h post-dose) was significantly more effective than vehicle for prevention of itching and conjunctival hyperemia (p < 0.001) and noninferior to olopatadine 0.1% (challenged 4 h post-dose). Significantly lower hyperemia scores were observed in alcaftadine-treated than olopatadine-treated eyes at 7 and 15 min post-CAC (p ≤ 0.027). Alcaftadine and olopatadine were well tolerated; no serious adverse events were reported. Conclusion: Alcaftadine 0.25% is effective in preventing signs and symptoms of Japanese cedar pollen-induced allergic conjunctivitis.


Subject(s)
Benzazepines/administration & dosage , Cedrus/adverse effects , Conjunctivitis, Allergic/prevention & control , Imidazoles/administration & dosage , Olopatadine Hydrochloride/administration & dosage , Pollen/adverse effects , Adult , Conjunctivitis, Allergic/epidemiology , Dose-Response Relationship, Drug , Double-Blind Method , Female , Follow-Up Studies , Histamine H1 Antagonists/administration & dosage , Humans , Incidence , Japan/epidemiology , Male , Ophthalmic Solutions/administration & dosage , Retrospective Studies , Seasons , Treatment Outcome
5.
Ann Nucl Med ; 29(9): 792-8, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26238440

ABSTRACT

OBJECTIVE: Technetium etarfolatide ((99m)Tc-EF) is a radioactive diagnostic imaging agent that was developed to assess the expression of folate receptors in tumors. Administering folic acid prior to the administration of (99m)Tc-EF has been shown to improve SPECT images. Here, we conducted a phase I clinical trial to assess the safety, pharmacokinetics, and radiation dosimetry of (99m)Tc-EF injection following pre-administration of folic acid in healthy Japanese male adults. METHODS: Six healthy Japanese male adults were enrolled in the study. Folic acid was intravenously administered, followed 1-3 min later by an intravenous injection of (99m)Tc-EF (740 MBq ± 20 %). Assessments of subjective symptoms and objective findings, electrocardiograms, physical examination, and laboratory tests were performed before and up to 7 days after the injection to assess the safety of (99m)Tc-EF. Blood and urine collections and whole-body planar imaging were conducted at various time points up to 24 h after the injection to assess the pharmacokinetics of (99m)Tc-EF. The internal radiation dosimetry was calculated based on the pharmacokinetics results using the MIRD method. RESULTS: Five adverse events were observed in three subjects (50 %) after administration of the folic acid and (99m)Tc-EF, while these events were mild and non-serious. Of those five events, three were considered to be related to the administered agents. The radioactivity in blood rapidly decreased and showed a biphasic profile. The activity of (99m)Tc-EF at 5 min post injection was largest in the bone marrow, followed by the liver and kidneys, and had decreased within 24 h in all organs/tissues without appreciable retention. The pharmacokinetics results suggested that (99m)Tc-EF was mainly eliminated by kidney. The results also suggested that when administered at 925 MBq of (99m)Tc-EF, which is the maximum dose generally used for clinical trials in other countries, the corresponding effective dose of (99m)Tc-EF is equal to or less than those determined for the current radioactive diagnostic imaging agents. CONCLUSIONS: The results of this study assessing the safety and radiation dosimetry of (99m)Tc-EF with folic acid pre-administration suggested that folic acid and (99m)Tc-EF should be appropriate for further studies. No pharmacokinetics concerns were noted.


Subject(s)
Folic Acid/analogs & derivatives , Folic Acid/administration & dosage , Organotechnetium Compounds , Radiopharmaceuticals , Vitamin B Complex/administration & dosage , Administration, Intravenous , Adult , Folate Receptors, GPI-Anchored/analysis , Folic Acid/adverse effects , Folic Acid/chemistry , Folic Acid/pharmacokinetics , Humans , Japan , Male , Molecular Structure , Organotechnetium Compounds/adverse effects , Organotechnetium Compounds/chemistry , Organotechnetium Compounds/pharmacokinetics , Radiometry , Radiopharmaceuticals/adverse effects , Radiopharmaceuticals/chemistry , Radiopharmaceuticals/pharmacokinetics , Time Factors , Whole Body Imaging/methods
6.
Metabolism ; 58(10): 1400-7, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19570554

ABSTRACT

Bariatric surgery has been shown to improve glucose tolerance, although the mechanism has not been fully elucidated. Animal studies have suggested important roles of bile acid (BA) as a regulator of energy homeostasis and glucose metabolism. However, little is known about its role in humans. We investigated the longitudinal changes of BA, incretins, and adipokines after significant weight reduction in 34 Japanese adults with morbid obesity who underwent laparoscopic bariatric surgery. In subjects who underwent malabsorptive or restrictive surgery, body mass index had markedly decreased from 43.0 +/- 6.5 (SD) to 37.8 +/- 5.7 kg/m(2) and from 45.3 +/- 11.2 to 41.5 +/- 10.5 kg/m(2), respectively, at 1 month after surgery. Glycated hemoglobin decreased from 6.1% +/- 1.5% to 5.2% +/- 0.4% and from 6.2% +/- 1.3% to 5.4% +/- 0.7%, and total BA level increased from 3.1 +/- 3.5 to 7.2 +/- 5.3 mumol/L and from 3.2 +/- 2.6 to 9.4 +/- 10.0 mumol/L, respectively. At baseline, serum concentration of primary BA was positively correlated with plasma gastric inhibitory polypeptide level (r = 0.548, P = .001); and change in primary BA level was positively correlated with changes in plasma gastric inhibitory polypeptide (r = 0.626, P = .001) and serum immunoreactive insulin level (r = 0.592, P = .002) at 1 month after surgery. Furthermore, plasma glucagon-like peptide-1 and serum high-molecular weight adiponectin levels increased in both surgeries. These hormonal changes might explain the mechanism(s) of improved glucose tolerance after bariatric surgery in morbidly obese subjects.


Subject(s)
Adiponectin/blood , Bariatric Surgery , Bile Acids and Salts/blood , Incretins/blood , Adipokines/blood , Adult , Body Mass Index , Female , Humans , Laparoscopy , Male , Middle Aged , Molecular Weight , Obesity, Morbid/blood , Obesity, Morbid/surgery
7.
Intern Med ; 48(12): 1037-9, 2009.
Article in English | MEDLINE | ID: mdl-19525594

ABSTRACT

Although recent studies recommended that insulin should be administered to patients with slowly progressive type 1 diabetes, even those with non-insulin dependent status, patients prefer oral hypoglycemic agents to insulin injections. We report a slowly progressive type 1 diabetic patient whose insulin production was preserved for 4 years (SigmaC-peptide from 29.48 ng/mL to 24.58 ng/mL) using pioglitazone despite a high titer of anti-GAD antibody (GADA; 120.7 U/mL). This case suggests that pioglitazone might prevent or delay the loss of insulin secretion and insulin dependency in slowly progressive type 1 diabetic patients.


Subject(s)
Diabetes Mellitus, Type 1/drug therapy , Hypoglycemic Agents/therapeutic use , Thiazolidinediones/therapeutic use , Administration, Oral , Diabetes Mellitus, Type 1/blood , Disease Progression , Humans , Hypoglycemic Agents/administration & dosage , Insulin/blood , Insulin/therapeutic use , Male , Middle Aged , Pioglitazone , Thiazolidinediones/administration & dosage
8.
Endocr J ; 55(2): 331-8, 2008 May.
Article in English | MEDLINE | ID: mdl-18362454

ABSTRACT

OBJECTIVE: Serum C-reactive protein (CRP) and adiponectin levels predict atherosclerosis and coronary heart disease. However, the efficacy of the combination of both markers remains unknown. In the present study, we investigated whether the combination of CRP and adiponectin is associated with further metabolic abnormalities compared to each of them alone. RESEARCH DESIGN AND METHODS: Eighty-three Japanese type 2 diabetic outpatients participated in this study. We measured serum high-sensitive CRP and high molecular weight (HMW)-adiponectin, and investigated their relationship with various metabolic parameters. RESULTS: In univariate analysis, CRP was significantly correlated with diastolic blood pressure and HDL-cholesterol. On the other hand, HMW-adiponectin was significantly correlated with systolic (SBP) and diastolic blood pressure, plasma glucose, HDL-cholesterol, triglycerides and HOMA-IR, but not with CRP. We then classified the subjects into three groups: low CRP and high HMW-adiponectin levels (low risk group, 19%), high CRP and low HMW-adiponectin levels (high risk group, 22%), and others. In Spearman rank correlation coefficient analysis, this classification was significantly associated with a larger number of metabolic risk factors: SBP, glucose, HbA1c, LDL-cholesterol, HDL-cholesterol, triglycerides and HOMA-IR, compared with classification by CRP or HMW-adiponectin alone. CONCLUSION: These results suggest that combination of CRP and HMW-adiponectin reflects further metabolic abnormalities compared with each of them in type 2 diabetic subjects. The combined measurement of both markers may be useful to detect cardiovascular high risk patients.


Subject(s)
Adiponectin/blood , Blood Glucose/metabolism , C-Reactive Protein/metabolism , Diabetes Mellitus, Type 2/blood , Insulin/metabolism , Aged , Biomarkers/blood , Blood Pressure/physiology , Body Mass Index , Cholesterol, HDL/blood , Diabetes Mellitus, Type 2/ethnology , Female , Humans , Insulin Resistance/physiology , Japan , Male , Middle Aged , Obesity/metabolism , Predictive Value of Tests , Triglycerides/blood
9.
Metabolism ; 57(2): 157-62, 2008 Feb.
Article in English | MEDLINE | ID: mdl-18191043

ABSTRACT

Adipokines play crucial roles in obesity-related insulin resistance in adults, but little is known in the general adolescent population. This study was designed to investigate the relationships between adipokines and metabolic parameters, the insulin resistance index, and proinflammatory cytokines in the general population of Japanese male adolescents. We studied 662 Japanese male high school students aged 16 to 17 years and 282 healthy Japanese male adults aged 30 to 61 years who received annual health checkups. High-molecular weight (HMW) adiponectin levels were significantly lower in adolescents (4.18 +/- 2.24 microg/mL) than in adults (4.84 +/- 3.20 microg/mL), despite body mass index (BMI) being significantly lower in adolescents. The HMW adiponectin levels correlated negatively with BMI and the homeostasis model assessment of insulin resistance index (HOMA-IR) in adults. In adolescents, HMW adiponectin correlated negatively with BMI and waist circumference, but not with HOMA-IR or other metabolic parameters except high-density lipoprotein cholesterol. Leptin levels correlated positively with HOMA-IR, triglycerides, tumor necrosis factor alpha, interleukin 6, and monocyte chemoattractant protein 1 and negatively with high-density lipoprotein cholesterol even after adjustment for BMI. These findings suggest that serum leptin is a more useful biomarker of fat accumulation-related insulin resistance, inflammation, and metabolic abnormalities than HMW adiponectin in the general population of male adolescents. The inverse correlation between adiponectin and insulin resistance may manifest in the later phase of obesity development.


Subject(s)
Leptin/blood , Adiponectin/blood , Adipose Tissue/metabolism , Adolescent , Adult , Blood Glucose/metabolism , Body Mass Index , Chemokine CCL2/blood , Cholesterol, HDL/blood , Humans , Insulin/blood , Insulin Resistance/physiology , Interleukin-6/blood , Japan , Male , Middle Aged , Regression Analysis , Triglycerides/blood , Tumor Necrosis Factor-alpha/blood
10.
Biochemistry ; 46(3): 792-8, 2007 Jan 23.
Article in English | MEDLINE | ID: mdl-17223700

ABSTRACT

Beta-amylase (EC 3.2.1.2) is starch-hydrolyzing exo-type enzyme that can catalyze the successive liberation of beta-maltose from the nonreducing ends of alpha-1,4-linked glucopyranosyl polymers. There is a well-known phenomenon called multiple or repetitive attack where the enzyme releases several maltose molecules in a single enzyme-substrate complex. In order to understand it further, we examined the beta-amylase-catalyzed reaction using maltooligosaccharides. The Monte Carlo method was applied for simulation of the beta-amylase-catalyzed reaction including the multiple attack mechanism. Through site-directed mutagenesis, we have successfully prepared a mutant enzyme which may be simulated as a multiple attack action reduced one with retaining significant hydrolytic activity. From the results of X-ray structure analysis of the mutant enzyme, it was clarified that one carboxyl residue plays a very important role in the multiple attack. The multiple attack action needs the force of enzyme sliding on the substrate. In addition, it is important for the multiple attack that the enzyme and substrate have the characteristics of a stable productive substrate-enzyme complex through a hydrogen bond between the nonreducing end of the substrate and the carboxyl residue of the enzyme.


Subject(s)
beta-Amylase/metabolism , Computer Simulation , Crystallization , Crystallography, X-Ray , Kinetics , Models, Chemical , Monte Carlo Method , Glycine max/enzymology , beta-Amylase/genetics
11.
Biochem J ; 365(Pt 3): 701-5, 2002 Aug 01.
Article in English | MEDLINE | ID: mdl-11965243

ABSTRACT

The action of hyaluronidase on oligosaccharides from hyaluronan is complicated due to branched reaction paths containing hydrolysis, transglycosylation and condensation. The unit component of hyaluronan is a disaccharide, namely GlcA-(beta 1-->3)-GlcNAc where GlcA and GlcNAc are d-glucuronic acid and d-N-acetylglucosamine respectively. Hyaluronan is the linear polymer formed by these disaccharide units, linked together with beta 1-->4 glycosidic bonds. Bovine testicular hyaluronidase acts only at beta 1-->4 glycosidic bonds of hyaluronan. The progress of product distribution from short oligosaccharides was simulated with the Monte Carlo method using the probabilistic model. The model consists only of a single enzyme molecule and a finite number of substrate and water molecules. The simulation is based on a simple reaction scheme and proceeds via an algorithm with minimum adjustable parameters generating random numbers and probabilities. The experimental data for bovine testicular hyaluronidase using [GlcA-(beta 1-->3)-GlcNAc](4) as the starting substrate were quantitatively simulated with only three adjustable parameters. The simulated data for [GlcA-(beta 1-->3)-GlcNAc](3) and [GlcA-(beta 1-->3)-GlcNAc](5) as the starting substrates agreed semi-quantitatively with experimental data using the same parameters. The mechanism of the hyaluronidase reaction is a combination of branched probabilistic cycles. The condensation reaction is much weaker than the transglycosylation reaction but contributes to product distribution at the final stage of the reaction, preventing complete hydrolysis of the substrates.


Subject(s)
Computer Simulation , Hyaluronic Acid/metabolism , Hyaluronoglucosaminidase/metabolism , Monte Carlo Method , Algorithms , Animals , Cattle , Glycosylation , Hyaluronoglucosaminidase/chemistry , Hydrolysis , Male , Mathematics , Testis/enzymology
SELECTION OF CITATIONS
SEARCH DETAIL
...